CSBR Champions Oncology, Inc. logo

CSBR Champions Oncology, Inc.

Healthcare
$6.01+1.59%ClosedMarket Cap: $83.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

19.49

P/S

1.44

EV/EBITDA

-105.22

DCF Value

$10.67

FCF Yield

4.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

45.9%

Operating Margin

-3.8%

Net Margin

-3.9%

ROE

-58.0%

ROA

-8.0%

ROIC

-23.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 null$16.6M$-279.0K$
Q2 null$15.0M$299.0K$
Q1 null$14.0M$-466.0K$
Q4 null$12.4M$-1.8M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$12.00

Target (Median)

$12.00

Target Range

$12.00 - $12.00

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Brainin Robert Lawrencedirector, officer: CEO
SellFri Jan 30
Brainin Robert Lawrencedirector, officer: CEO
SellFri Jan 30
Brainin Robert Lawrencedirector, officer: CEO
SellFri Jan 30
Brainin Robert Lawrencedirector, officer: CEO
SellFri Jan 30
Brainin Robert Lawrencedirector
SellFri Jan 30

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.43

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Peers